Abcodia is a technology company.
Abcodia is a technology company.
Abcodia has raised $8.0M across 1 funding round.
Abcodia has raised $8.0M in total across 1 funding round.
Abcodia has raised $8.0M in total across 1 funding round.
Abcodia's investors include Cambridge Innovation Capital.
Abcodia is a clinical-stage biotechnology company that develops diagnostic tests for early cancer detection, primarily using biomarker analysis from blood samples.[1][2][3] Its flagship product is a blood test based on the Risk of Ovarian Cancer Algorithm (ROCA) for screening ovarian cancer before symptoms appear, targeting healthcare providers and patients in need of proactive screening solutions.[1][2] The company leverages a unique access to the UKCTOCS serum biobank with millions of samples from healthy volunteers to validate biomarkers for cancers and age-related diseases, addressing the critical problem of late-stage diagnoses that reduce survival rates.[3][4]
Founded as a spin-out from University College London, Abcodia achieved early recognition with multiple UK Startup Awards in 2012 and partnerships like those with Cancer Research UK, but was ultimately acquired by GENinCode in 2022, marking the end of its independent operations.[2][3][8]
Abcodia was founded in 2010 as a spin-out from University College London (UCL), securing exclusive commercialization rights to a serum biobank from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), led by Professors Ian Jacobs and Usha Menon at UCL's Institute for Women's Health.[2][3] The biobank includes over 5 million serum samples from more than 200,000 initially healthy volunteers, with 50,000 providing annual samples, enabling prospective biomarker discovery.[4] CEO Dr. Julie Barnes, honored as Business Woman of the Year in 2012, drove early momentum; the company won four UK Startup Awards that year, including overall NatWest Startups Business of the Year for its cancer screening innovations.[2]
Pivotal early moves included a 2013 exclusive license for the ROCA test and collaborations with Cancer Research UK and partners like Caprion for proteomics, building on UCL's clinical trial data to validate pre-symptomatic biomarkers.[2][3]
Abcodia rode the wave of precision oncology and liquid biopsy trends in the 2010s, emphasizing blood-based screening to shift cancer detection from reactive to preventive, amid rising demand for non-invasive diagnostics.[1][2][5] Timing aligned with large-scale trials like UKCTOCS, providing rare prospective data that fueled biomarker R&D when genomic sequencing costs plummeted, enabling scalable validation.[3][4] Market forces like aging populations and ovarian cancer's high mortality from late detection favored its focus, influencing the ecosystem by validating biobank models for biotech spin-outs and attracting partnerships that advanced proteomics and immune monitoring in early detection.[3]
Post-2022 acquisition by GENinCode, Abcodia's assets likely integrate into broader genetic risk and diagnostics platforms, amplifying its biobank and ROCA tech in personalized medicine.[8] Trends like AI-driven biomarker analysis and multi-cancer early detection tests (e.g., Galleri-inspired approaches) will shape its legacy, potentially evolving GENinCode's offerings amid regulatory pushes for validated screening. This positions it to influence scalable, population-level cancer prevention, tying back to its origins in transforming UCL trial data into life-saving tools.
Abcodia has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series B in May 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2015 | $8.0M Series B | Cambridge Innovation Capital |